Andera Partners structures its single fund to include early (20%), mid (50%), and late-stage (30%) companies. This mixed-stage approach allows them to generate earlier liquidity from mature assets to satisfy investors (LPs), which in turn enables them to take long-term bets on nascent biotechs without needing separate, stage-specific funds.
Venture capitalists have their own fundraising pressures and obligations to their LPs. Founders who understand that VCs need to generate returns to raise their next fund can build a more strategic and aligned relationship. This empathy helps in navigating milestone discussions and exit strategies, moving beyond a simple capital provider-recipient dynamic.
Scientific failure is an acceptable risk in biotech, but failure from preventable errors like poor trial design, regulatory oversights, or market access neglect is not. A key role for a VC is to provide expertise to mitigate these “bad” reasons for failure, ensuring capital is spent testing the core scientific hypothesis, not on operational mistakes.
While hype cycles focus on novel areas, significant value exists in established markets like hypertension. By targeting refractory patient populations with high unmet needs (e.g., the 20% of hypertension patients not properly treated), biotechs can create valuable assets with novel mechanisms in fields that appear saturated.
Tranche financing is a rational tool for early-stage companies to tie capital to specific de-risking milestones. However, it's illogical for later-stage companies running large, pivotal trials. For a Phase 3 study, there is no value in withholding capital, as the full amount is necessary to reach the singular, long-term data readout.
To rival the US and China, a coalition of European VCs is focusing on three pillars: 1) simplifying and speeding up regulations, 2) attracting more institutional capital (e.g., pension funds) into life sciences, and 3) building a robust, NASDAQ-like public market to foster growth and retain wealth generation within Europe.
The most effective first-time CEOs don't just pitch; they continuously build a diverse network of advisors and peers, absorbing feedback to constantly refine their strategy and story. This approach demonstrates coachability and builds a more credible, balanced narrative for investors, who are wary of a pure sales pitch that hides underlying risks.